Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 4 September 2018, 09:00 HKT/SGT
Share:
    

Source: Cadrock Pte Ltd
Cadrock Secures US$5m for Therapy Targeting $35 billion Heart Disease Market
- Enrolls first clinical trial patients in Sydney, Australia

SYDNEY, Sept 4, 2018 - (ACN Newswire) - Cadrock Pty Ltd, which owns an investigational prevention and treatment therapy for coronary artery disease (CAD), has secured a US$5 million seed investment from a Chinese investor to fund clinical trials.


Professor Thomas Borody


Cadrock is potentially disrupting the entire heart-care sector by proposing CAD is caused by bacterial infection.

Cadrock data is backed by a clinical trial treating CAD as an infection with an antibiotic therapy in London, UK, which demonstrated a 36% reduction in Major Cardiac Events (MCEs) (STAMINA).

"Where there is inflammation, look for infection," says Professor Borody, who is well known globally for discovering the cure for the peptic ulcer bacterial infection, using a triple antibiotic therapy.

His triple antibiotic therapy for peptic ulcers prevented 18,655 premature deaths and saved the Australian Government an estimated AU$10.03 billion (THEMA Report).

Professor Borody has now developed and patented a new investigational triple antibiotic therapy to combat the infection believed to cause CAD.

"The Cadrock therapy is targeting the $35 billion CAD market and is the only therapy focused on the cause of CAD rather than suspected risk factors," said Professor Borody.

The first Cadrock interventional clinical trial of the triple therapy at Liverpool Hospital, Sydney Australia, has just enrolled its second patient.

The study is recruiting 60 people with CAD and will "evaluate the effect of antibiotic combination therapy on objective measures of improvement in coronary flow as determined by fractional flow reserve (FFR) intra-coronary imaging (Intravascular ultrasound [IVUS] and/or Optical Coherence Tomography [OCT]) in subjects undergoing percutaneous coronary intervention (PCI) with non-critical lesions in non-culprit arteries."

Professor Borody is most famous for discovering the triple antibiotic therapy for peptic ulcers in 1985, after Nobel Prize recipients Barry Marshall and Robin Warren discovered infection as the cause.

Professor Borody said, "CAD heart disease and stroke are the world's biggest killers with around 15 million deaths in 2015. In the US alone heart disease is the leading cause of death for both men and women - 610,000 people die of heart disease in the United States annually. (Source: CDC).

In China, about 230 million or 1/5 people have cardiovascular disease. (Source: Harvard University)

Additionally, peripheral vascular disease worldwide afflicts around 200 million people.

Statins form part of the first line treatment of CAD but reduce Major Cardiac Events (MCEs) in preventative studies by as little as 0.2-0.6%. (Jupiter)

About Cadrock (http://www.cadrockacac.com)

Cadrock Pty Ltd has a novel investigational prevention and treatment therapy for coronary heart disease (CAD) developed by Professor Thomas Borody, who discovered the cure for peptic ulcers. The Cadrock therapy is targeting the $35 billion CAD market and is the only therapy focused on the cause of CAD, rather than suspected risk factors. The Cadrock therapy is now in clinical trials in Australia. For more information, and access to the Digify investor VDR, please contact investor relations at [email protected].



Sept 4, 2018 09:00 HKT/SGT
Topic: Press release summary
Sectors: BioTech, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
VPower Group Begins Operation of 38.8MW Power Stations in Sri Lanka  
July 6, 2020 18:40 HKT/SGT
Announcement of Absorption-type Merger (Simplified Merger and Short-form Merger) of DENSO IT Solutions Inc.  
July 6, 2020 15:34 HKT/SGT
Privity FZ LLE participates in Verofax pre-seed investment round  
July 6, 2020 15:30 HKT/SGT
JGA North is Ready for Service  
July 6, 2020 14:30 HKT/SGT
Aichi Cancer Center and NEC Launch Joint Research on Fundamental Study Aimed at Advanced Cancer Immunotherapy  
July 6, 2020 14:11 HKT/SGT
Toyota Reproduces and Sells Spare Parts for 2000GT  
July 6, 2020 12:37 HKT/SGT
Favored by Capital Market Again, MicroPort's CRM Business Brings in New Investor  
July 6, 2020 11:15 HKT/SGT
VIET CAPITAL BANK and 7-ELEVEN VIETNAM Launch JCB CARD  
July 6, 2020 11:00 HKT/SGT
Fujitsu Embarks Towards 'New Normal', Redefining Working Styles for its Japan Offices  
July 6, 2020 10:47 HKT/SGT
Privity FZ LLE participates in Verofax pre-seed investment round  
July 6, 2020 10:40 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: